An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
Merus still hopes for a future for MCLA-129, but the doors are closing.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
Yet another ADC deal sees AbbVie buy ImmunoGen, ending a 40-year rollercoaster ride with a 100% overnight premium.
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.
Against the odds GSK’s Dreamm-7 study yields a positive survival readout.